| Nick's Health Care Center, Llc | |
| 253 East Highway 116, Plattsburg, Missouri 64477 | |
| (816) 539-2376 | |
| Name | Nick's Health Care Center, Llc |
|---|---|
| Location | 253 East Highway 116, Plattsburg, Missouri |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 70 |
| Occupancy Rate | 92.86% |
| Medicare ID (CCN) | 265698 |
| Legal Business Name | Nicks Health Care Center, Llc |
| Ownership Type | For Profit - Individual |
| NPI Number | 1679569057 |
| Organization Name | N & R OF PLATTSBURG, LLC |
| Doing Business As | CLINTON CARE & REHAB CENTER |
| Address | 253 E Highway 116, Plattsburg, MO 64477 |
| Phone Number | 816-539-2376 |
News Archive
Recently, scientists demonstrated the anti-cancer effects of silibinin, a major biologically active compound of milk thistle. Being widely used as a folk remedy for liver diseases, milk thistle is safe and well-tolerated, and it protects the liver from drug or alcohol-related injury.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
A study published in Cancer Prevention Research , a journal of the American Association for Cancer Research, identifies components of black raspberries with chemopreventive potential.
› Verified 4 days ago
| NPI Number | 1780064071 |
| Organization Name | NICK'S HEALTH CARE CENTER LLC |
| Address | 253 E Highway 116, Plattsburg, MO 64477 |
| Phone Number | 816-539-2376 |
News Archive
Recently, scientists demonstrated the anti-cancer effects of silibinin, a major biologically active compound of milk thistle. Being widely used as a folk remedy for liver diseases, milk thistle is safe and well-tolerated, and it protects the liver from drug or alcohol-related injury.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
A study published in Cancer Prevention Research , a journal of the American Association for Cancer Research, identifies components of black raspberries with chemopreventive potential.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Recently, scientists demonstrated the anti-cancer effects of silibinin, a major biologically active compound of milk thistle. Being widely used as a folk remedy for liver diseases, milk thistle is safe and well-tolerated, and it protects the liver from drug or alcohol-related injury.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.
A study published in Cancer Prevention Research , a journal of the American Association for Cancer Research, identifies components of black raspberries with chemopreventive potential.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 4 |
| Total Amount of Fines in Dollars | $4550 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 4 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10.53 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 0.41 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 7.01 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.46 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.4 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.92 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.97 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 85.87 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 57.14 | 14.2 |